These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 17407395)

  • 21. Intravenous immunoglobulin utilization in the Canadian Atlantic provinces: a report of the Atlantic Collaborative Intravenous Immune Globulin Utilization Working Group.
    Constantine MM; Thomas W; Whitman L; Kahwash E; Dolan S; Smith S; Caudle CJ; Burton E; Anderson DR;
    Transfusion; 2007 Nov; 47(11):2072-80. PubMed ID: 17958537
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
    Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
    J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comment on "Pharmacoeconomics of therapy for Guillain-Barré syndrome: plasma exchange and intravenous immunoglobulin".
    Buenz EJ
    J Clin Neurosci; 2009 Aug; 16(8):1110; author reply 1111. PubMed ID: 19467870
    [No Abstract]   [Full Text] [Related]  

  • 24. [The new domestic immunoglobulin G gabriglobin in complex therapy of immunodeficiency states and infectious pathology].
    Pas'ko VG; Latysheva TV; Nikiforov VV; Mostovskaia EV; Denisov AK; Kondrashin IuI
    Voen Med Zh; 2006 Jul; 327(7):40-2. PubMed ID: 16977880
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
    Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
    J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Withdrawing of IVIG compound from the market].
    Shoenfeld Y
    Harefuah; 2010 Dec; 149(12):754-5. PubMed ID: 21916093
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of intravenous immunoglobulin in the treatment of immune-mediated demyelinating diseases of the nervous system.
    Winkelmann A; Zettl UK
    Curr Pharm Des; 2012; 18(29):4570-82. PubMed ID: 22612749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indications and safety of intravenous and subcutaneous immunoglobulin therapy.
    Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD
    Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The product: All intravenous immunoglobulins are not equivalent.
    Siegel J
    Pharmacotherapy; 2005 Nov; 25(11 Pt 2):78S-84S. PubMed ID: 16229678
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [IgIV at home:experience of a center--economic aspects].
    Hachulla E
    Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of Polyclonal Intravenous Immunoglobulin at a Paediatric Referral Hospital in South Africa Between 2009 and 2012.
    Raiman S; Knight SE; Eley B; Welzel TB
    J Clin Immunol; 2015 Oct; 35(7):668-74. PubMed ID: 26369911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Positive clinical outcome with IVIg as monotherapy in recurrent pemphigoid gestationis.
    Nguyen T; Alraqum E; Razzaque Ahmed A
    Int Immunopharmacol; 2015 May; 26(1):1-3. PubMed ID: 25765353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Selecting a polyclonal immune globulin treatment for a patient with primary immune deficiency disease: Role of the clinical pharmacist.
    Tichy EM; Vaughan L
    Am J Health Syst Pharm; 2016 Apr; 73(8):533-46. PubMed ID: 27045066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Appropriate use of intravenous immunoglobulin in neonatal neutropenia.
    Buenz EJ; Howe CL
    J Perinatol; 2007 Mar; 27(3):196-7; author reply 197. PubMed ID: 17314992
    [No Abstract]   [Full Text] [Related]  

  • 36. [Expert opinion on use of intravenous immunoglobulins in the management of neurological disorders].
    Stępień A; Korsak J; Kozubski W; Ryglewicz D; Losy J; Drozdowski W; Kotowicz J; Nyka W; Kwieciński H
    Neurol Neurochir Pol; 2011; 45(6):525-35. PubMed ID: 22212982
    [No Abstract]   [Full Text] [Related]  

  • 37. Human intravenous immunoglobulin-induced aseptic meningitis: a case report.
    Chaabane A; Hamzaoui A; Aouam K; Klai R; Fredj NB; Boughattas NA; Mahjoub S
    J Clin Pharmacol; 2012 Feb; 52(2):279-81. PubMed ID: 21257801
    [No Abstract]   [Full Text] [Related]  

  • 38. Complications of intravenous immune globulin treatment in neurologic disease.
    Achiron A
    Neurology; 1997 Sep; 49(3):899-900. PubMed ID: 9305372
    [No Abstract]   [Full Text] [Related]  

  • 39. Application of pharmacoeconomics to formulary management in a health system setting.
    Studdert AL; Gong CL; Srinivas S; Chin AL; Deresinski S
    Am J Health Syst Pharm; 2019 Feb; 76(6):381-386. PubMed ID: 31361838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of hypogammagammaglobulinemia on infection outcome in patients undergoing ventricular assist device implantation.
    Ankersmit HJ; Hacker S; Hoetzenecker K; Moser B; Wolner E
    J Heart Lung Transplant; 2006 Nov; 25(11):1387-8. PubMed ID: 17097508
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.